       Document 0451
 DOCN  M9610451
 TI    A rapid antiviral in situ enzyme-linked immunosorbent assay for feline
       immunodeficiency virus.
 DT    9601
 AU    Smith JL; Allen SJ; Cherrington JM; Gilead Sciences Inc., Foster City,
       CA 94404, USA.
 SO    J Virol Methods. 1995 Jul;54(1):29-38. Unique Identifier : AIDSLINE
       MED/96040133
 AB    An in situ enzyme-linked immunosorbent assay (ELISA) was developed as a
       rapid alternative to the focal infectivity assay (FIA) for screening
       potential anti-retroviral molecules. The assay utilizes 96-well
       microtiter plates to allow for determination of antiviral effect and
       cytotoxicity of multiple compounds simultaneously. In contrast to the
       FIA which requires visual scoring of foci under low-power microscopy,
       the 96-well ELISA is read spectrophotometrically based on the soluble
       alkaline phosphatase substrate, p-nitrophenyl phosphate. The IC50 and
       CC50 values for several antiretroviral compounds were determined using
       the ELISA and results were confirmed by FIA. In all cases, compounds
       assayed by the newly described ELISA exhibited IC50 values in agreement
       with literature values derived from either the FIA or reverse
       transcriptase assays.
 DE    Animal  Antibodies, Viral/ANALYSIS  Antiviral Agents/PHARMACOLOGY  Cell
       Line  Enzyme-Linked Immunosorbent Assay/*METHODS  Immunodeficiency
       Virus, Feline/IMMUNOLOGY/*ISOLATION & PURIF  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

